Patent application number | Description | Published |
20090023730 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION - The invention provides compounds and pharmaceutically acceptable salts of Formula I | 01-22-2009 |
20090041720 | HETEROARYL SUBSTITUTED THIAZOLES - The invention provides heteroaryl substituted thiazolo compounds of Formula I and II | 02-12-2009 |
20090048297 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I | 02-19-2009 |
20090304605 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity - The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II | 12-10-2009 |
20100292219 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION - The present invention provides tertiary amine substituted peptides of Formula (I) useful as inhibitors of HCV replication. The variables R and R | 11-18-2010 |
20140113890 | NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides of Formula I | 04-24-2014 |
20150239838 | Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer. | 08-27-2015 |
20150239868 | Alkyne Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 08-27-2015 |
20150239893 | Amide Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 08-27-2015 |
20150239894 | Amino Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 08-27-2015 |
20150239895 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 08-27-2015 |
20150239919 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R | 08-27-2015 |
20150239920 | Ether Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 08-27-2015 |
20150239921 | Phosphonate Compounds for Treatment of Complement Mediated Disorders - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 08-27-2015 |